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ABSTRACT21 
Autophagy seems to play a role in the etiology and progress of misfolded protein 22 
disorders. Although this process is dysregulated in prion diseases, it is still unknown if 23 
this impairment is a cause or a consequence of prion neuropathology. The study of 24 
autophagy during the progress of the disease could elucidate its role. For this purpose, 25 
we have investigated its regulation at different stages of the disease in Tg338 mice, a 26 
transgenic murine model that overexpresses the highly susceptible ovine VRQ prion 27 
protein allele. Mice were intracerebrally inoculated with mouse-adapted classical 28 
scrapie and euthanized at preclinical and clinical stages of the disease. Regulation of 29 
autophagy was investigated analyzing the distribution of LC3-B and p62 proteins by 30 
immunohistochemistry. Moreover, the expression of genes involved in autophagy 31 
regulation was quantified by real-time PCR. LC3-B and p62 proteins were 32 
downregulated and upregulated, respectively, in the central nervous system of infected 33 
mice with clinical signs of scrapie. Accumulation of p62 correlated with scrapie-related 34 
lesions suggesting an impairment of autophagy in highly prion-affected areas. In 35 
addition, Gas5, Atg5 and Fbxw7 transcripts were downregulated in mesencephalon and 36 
cervical spinal cord of the same group of animals. The impairment of autophagic 37 
machinery seems to be part of the pathological process of scrapie but only during the 38 
late stage of prion infection. Similarities between Tg338 mice and the natural ovine 39 
disease make them a reliable in vivo model to study prion infection and autophagy side 40 
by side. 41 
42 
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INTRODUCTION 43 
Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are 44 
fatal infectious neurodegenerative disorders that affect both humans and animals [1]. 45 
They include the various forms of Creutzfeldt-Jakob disease in humans, bovine 46 
spongiform encephalopathy in cattle, and scrapie in sheep and goats, which is one of the 47 
first identified TSEs [2]. The causative agents of TSEs are prions, misfolded isoforms of 48 
the physiological cellular prion protein (PrPc), named PrP “scrapie” (PrPSc) [1]. Prions 49 
accumulate into the central nervous system (CNS), which is believed to be the main 50 
pathogenic event responsible for the pathological changes produced in TSE patients, 51 
including spongiform degeneration, vacuolization, glial activation and neuronal loss [3, 52 
4]. Prion diseases share common neurodegenerative features with other protein-53 
misfolding diseases like Alzheimer’s (AD), Huntington’s (HD) and Parkinson’s (PD) 54 
diseases [5]. However, the underlying pathomolecular mechanisms of this 55 
heterogeneous group of diseases are incompletely understood. 56 
Autophagy is one of the most relevant protein homeostasis systems, and is involved in 57 
the degradation of damaged organelles and altered proteins from the cell via the 58 
lysosomal pathway [6]. In autophagic degradation, a double-membraned vacuole called 59 
autophagosome engulfs the cytoplasmic cargo and eventually fuses with lysosomes to 60 
form autophagolysosomes, where hydrolytic enzymes digest and recycle the luminal 61 
content [7]. Autophagic activity requires multiple proteins, such as MAP1LC3 62 
(microtubule-associated protein 1 light chain 3), or LC3, and SQSTM1 (sequestosome 63 
1), also known as p62. Whereas LC3 is tightly associated to the autophagosomal 64 
membrane and is therefore considered a reliable marker of autophagy [8], p62 is an 65 
important cargo receptor located throughout the cell and specifically degraded by 66 
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autophagy [9]. Consequently, the evaluation of p62 accumulation has become a useful 67 
assay to estimate defects in autophagic degradation [8-11]. 68 
Dysfunction of the autophagic-lysosomal pathway is associated with the progression of 69 
several pathologies, including neurodegenerative diseases [12]. Indeed, there is 70 
substantial evidence that autophagy is dysregulated in pathologies like AD, HD, PD and 71 
TSEs [13-17], contributing to the accumulation of misfolded protein aggregates and 72 
neuronal death. Since drug-induced stimulation of autophagy flux produces anti-prion 73 
effects [18-25], autophagy is now emerging as a neuronal defense response in 74 
controlling prion infection, facilitating the clearance of aggregation-prone proteins and 75 
conferring a neuroprotective effect against prion-mediated neurotoxicity. 76 
The presence of autophagic vacuoles is well demonstrated in experimentally induced 77 
scrapie, in the natural human prion disease and in other experimental models of TSE 78 
[26-30]. Using sheep naturally affected with classical scrapie as a natural TSE animal 79 
model we described earlier an altered, brain region-dependent regulation of autophagy 80 
[31]. The downregulation of transcripts for two autophagy-related genes, ATG5 and 81 
ATG9, and the accumulation of p62 but not LC3, suggested an extensive decrease of the 82 
autophagic activity in injured CNS. However, the increased expression of LC3 and p62 83 
proteins in some specific neuronal populations indicated that autophagy was still active 84 
in less lesioned areas. Our subsequent study in induced ovine atypical scrapie confirmed 85 
the impairment of autophagy in highly prion-affected brain areas [32]. However, 86 
whether autophagic dysregulation is a cause or a consequence of prion-induced toxicity 87 
is still unknown.  88 
Besides naturally infected animals, experimentally induced murine models are 89 
extremely useful for careful monitoring the disease progression and, especially, for 90 
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studies of early stages of the pathology. The aim of the present study was to validate if 91 
the Tg338 mice that overexpress the ovine VRQ (V136R154H171) allele for the PRNP 92 
(prion protein) gene related to high susceptibility to scrapie [33] can serve as a reliable 93 
model to mimic autophagy changes observed in the natural model. For this purpose, 94 
autophagy regulation was investigated through the immunohistochemical determination 95 
of LC3-B and p62 in Tg338 mice infected with ovine scrapie and the relationship 96 
between autophagy markers and scrapie-related lesions was analyzed. Moreover, as the 97 
use of murine models may facilitate the study of disease-associated molecular 98 
mechanisms, we investigated the regulation of selected mRNAs and non-coding RNAs 99 
involved in autophagic machinery in mesencephalon and cervical spinal cord of Tg338 100 
mice at different stages of the disease.  101 
MATERIALS AND METHODS 102 
Animals and sample processing 103 
Mouse bioassay was performed in Tg338 mice, a transgenic murine model that express 104 
in the brain the VRQ allele of the ovine PRNP gene at levels 8- to 10-fold higher than 105 
those detected in sheep brains [33]. All inocula were prepared manually in sterile saline 106 
as 10% CNS homogenates and were cultivated in blood agar plates to test for the 107 
absence of bacterial contamination. Intracerebral inoculations were performed under 108 
gaseous anesthesia using 50-µl syringes and 25-gauge hypodermic needles inserted into 109 
the right frontal lobe, delivering 20 µl of the brain homogenate to each animal. To 110 
reduce post-inoculation pain, a subcutaneous injection of buprenorphine (0.3 mg/kg) 111 
was administered to each mouse before recovery to consciousness. 112 
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Two groups of 6 mice of 49 and 53 days of age were inoculated using the same Tg338-113 
adapted classical scrapie source. This inoculum was prepared as a pool of cervical 114 
spinal cord tissues from clinically-infected Tg338 mice previously inoculated with CNS 115 
material from a naturally scrapie-affected ARQ/ARQ sheep. In order to study autophagy 116 
at the preclinical and clinical stages of the prion disease, one of these groups 117 
(preclinical) was inoculated with a delay of 55 days with respect to the first one 118 
(clinical). Two other groups of 6 mice were intracerebrally inoculated at equivalent 119 
times with an inoculum obtained from CNS of non-inoculated Tg338 mice. They were 120 
selected as age-matched controls for the preclinical and clinical groups of mice. The 121 
experimental groups are listed in Supplementary Table 1. 122 
After inoculation, the mice were housed in filtered cages and their clinical status was 123 
monitored three times a week. Mice of the clinical group were euthanized when 124 
progression of the disease was evident upon detection of clinical signs of terminal prion 125 
disease. Mice from the preclinical and control groups were euthanized when the last 126 
mouse from the clinical group succumbed to the disease. After euthanasia, brains were 127 
harvested and divided sagittally. One hemisphere was immediately frozen in dry ice and 128 
conserved at -80 ºC and the other one was fixed by immersion in 10% formalin for up to 129 
48 hours (h). From each mouse a section of mesencephalon (Mes) and a caudal section 130 
of the brain, including cervical spinal cord (SC), were preserved in RNAlater for gene 131 
expression study. 132 
Neuropathological evaluation 133 
Tg338 brains fixed in formalin were embedded in paraffin wax, cut into 4-µm-thick 134 
sections and mounted on glass slides for morphological evaluation using haematoxylin 135 
and eosin (HE) staining. Analysis of PrPSc deposition was performed using the paraffin-136 
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embedded tissue (PET) blot method as previously described [34]. Briefly, paraffin-137 
embedded sections (4 µm) were collected onto nitrocellulose membranes (0.45 μm pore 138 
size; Bio-Rad) and digested with 250 μg/ml of proteinase K for 2 h at 56 ºC. Membrane-139 
attached proteins were denatured with 3M guanidine thiocyanate (Sigma-Aldrich) and 140 
PrPSc was detected using Sha31 mouse monoclonal antibody (1:8000 dilution for 1 h; 141 
SPI-Bio). Sections were then incubated with an alkaline phosphatase-coupled goat anti-142 
mouse antibody (1:500 dilution for 1 h; Dako) and enzymatic activity was visualized 143 
using NBT/BCIP chromogen (Sigma-Aldrich).  144 
Immunohistochemical analysis of autophagy markers 145 
Paraffin-embedded CNS tissue sections from Tg338 mice were studied by 146 
immunohistochemistry (IHC) to evaluate the brain expression and distribution of LC3-147 
B and p62 autophagy-related proteins. After deparaffination and rehydration, sections 148 
were pre-treated by heat-induced epitope retrieval for 20 minutes at 96 ºC in a PTLink 149 
(Dako), using Tris EDTA buffer (pH 9.0). Endogenous peroxidase activity was then 150 
blocked and samples were incubated for 1 h at room temperature with the following 151 
primary antibodies: mouse monoclonal anti MAP-LC3β (1:200 dilution; G-2, sc-152 
271625; Santa Cruz Biotechnology) and rabbit polyclonal anti p62 (1:200 dilution; 153 
PW9860; Enzo Life Sciences). Omission of the primary antibody served as a 154 
background control for nonspecific binding of the secondary antibody. Subsequently, 155 
the enzyme-conjugated polymer EnVision (Dako EnVision anti-mouse for MAP-LC3β; 156 
Dako EnVision anti-rabbit for p62) was used as visualization system followed by an 157 
incubation with diaminobenzidine chromogen (Dako).  158 
Quantification of gene expression  159 
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Five genes, described to be involved in autophagic machinery, were selected for the 160 
analysis of their expression profile in mesencephalon (Mes) and cervical spinal cord 161 
(SC) of Tg338 mice: Atg5 (autophagy-related 5), Lc3, Fbxw7 (F-box and WD repeat 162 
domain containing 7), p62 and Gas5 (growth arrest-specific 5). Supplementary Table 2 163 
shows TaqMan assays (Thermo Fisher Scientific) used for the amplification of the 164 
genes of interest. Total RNA was isolated from RNAlater-conserved Mes and SC, using 165 
the Direct-ZolTM RNA kit (Zymo Research). Retrotranscription was performed from 166 
200 ng of total RNA using qScriptTM cDNA Supermix (Quanta BiosciencesTM), 167 
according to the manufacturer´s instructions. Resulting complementary DNA was 168 
diluted 1:5 in water and gene expression was quantified by quantitative real-time PCR 169 
using the TaqMan universal PCR master mix assays (Thermo Fisher Scientific) in a 170 
StepOne Plus Real-Time PCR instrument (Applied Biosystems). All reactions were run 171 
in triplicate and universal amplification conditions were used. Expression levels of 172 
autophagy-related genes were normalized with Sdha housekeeping gene 173 
(Supplementary Table 2).  174 
Data analysis 175 
Histopathological lesions (i.e. spongiform changes), and LC3-B and p62 176 
immunolabelling, were evaluated in each brain section under a Zeiss Axioskop 40 177 
optical microscope, whereas the intensity and distribution of PrPSc deposition were 178 
analyzed with a Zeiss Stemi DV4 stereomicroscope. A semi-quantitative approach was 179 
used to obtain comparable data from the different lesions and autophagy markers in a 180 
total of 9 brain regions described by Fraser and Dickinson [35]: frontal cortex (Fc), 181 
septal area (Sa), thalamic cortex (Tc), hippocampus (Hc), thalamus (T), hypothalamus 182 
(Ht), mesencephalon (Mes), cerebellum (Cbl) and medulla oblongata (Mo). Each area 183 
9 
was investigated globally as a region for the scoring, except for Cbl, whose layers 184 
[molecular layer (Ml), Purkinje layer (Pl), granular layer (Gl), white matter (Wm) and 185 
deep cerebellar nuclei (DCN)] were analyzed separately in order to obtain a more 186 
detailed description. Brain regions studied were scored blindly and separately for the 187 
degree of spongiosis, PrPSc deposition and autophagy proteins on a scale ranging from 0 188 
(absence of spongiosis or immunolabelling) to 5 (maximum intensity of 189 
neuropathological lesions or immunolabelling). 190 
Significant differences of spongiform changes, PrPSc deposition profiles and LC3-B and 191 
p62 protein distribution between the experimental mouse groups were evaluated using 192 
the non-parametric Mann Whitney U test. Relative gene expression quantification was 193 
determined using the 2-ΔΔCt method and results were analyzed with the Student´s t-test. 194 
Previously, normal distribution of data was confirmed using the Shapiro-Wilk test. 195 
Correlations between autophagy proteins immunostaining and histopathological lesions 196 
were determined using the non-parametric Spearman´s rank correlation coefficient (rho, 197 
ρ). We used IBM® SPSS® statistics 22 software for all data analysis, and GraphPad 198 
Prism version 6.0 to perform the graphs. In all tests, the results were considered 199 
significant at P < 0.05.  200 
RESULTS 201 
Clinical signs of murine prion disease in Tg338 mice inoculated with ovine scrapie 202 
The mouse-adapted classical scrapie inoculum used in the present study transmitted 203 
with 100% attack rate in the group of Tg338 mice intended for autophagy evaluation in 204 
the clinical stage of the disease (clinical group). These mice were euthanized with 205 
terminal clinical signs compatible with TSE at ∼170 days post-inoculation (dpi) and 206 
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aged ∼219 days (Supplementary Table 1). Early clinical signs included mild dorsal 207 
kyphosis, tail rigidity and poor hair coat. Subsequently, mice developed clinical signs of 208 
terminal disease including severe ataxia, blepharitis, weight loss and hunched stance. In 209 
contrast, mice inoculated with a delay of 55 days were euthanized at 136 dpi without 210 
clinical signs (preclinical group). Control mice inoculated with healthy Tg338 brain 211 
material and euthanized after 136 (age-matched controls for preclinical mice) or 191 dpi 212 
(age-matched controls for clinical mice) did not display signs of disease. 213 
Histopathological profiles and PrPSc deposition patterns in the CNS of scrapie-214 
inoculated Tg338 mice are similar to those described in classical scrapie sheep 215 
Clinical Tg338 mice showed a significant increment of spongiform changes in all brain 216 
areas evaluated compared to their control group, except for Cbl (Supplementary Fig. 217 
1a). In these animals, T, Ht, Mes and Mo displayed the most severe spongiform lesions, 218 
while lesions were moderate in Hc and cerebral cortex and minimal in Cbl. Preclinical 219 
and control groups displayed minimal spongiform lesion scores. In addition, lesion 220 
scores for clinically-affected mice were also significantly higher than those for the 221 
preclinical group in T, Ht, Mes and Mo. No significant changes were detected when 222 
comparing mice at preclinical stage to their age-matched control group, neither between 223 
mock-treated control groups. 224 
All Tg338 mice that had developed clinical signs were positive for PrPSc accumulation 225 
in the brain (see representative PET blot in Supplementary Fig. 1b). In this group of 226 
animals, PrPSc deposition was especially remarkable in Mes, Ht and Mo. However, Mo 227 
showed large variability in PrPSc deposition intensity between clinical animals, leading 228 
to a high deviation in the semi-quantitative scoring. No PrPSc deposition was detected in 229 
mice at preclinical stage.  230 
11 
 
LC3-B protein is downregulated and p62 is upregulated in some highly-affected 231 
brain areas of scrapie-infected Tg338 mice at clinical stage 232 
Immunohistochemical determination of LC3-B and p62 in Tg338 mice revealed 233 
differential regulation of autophagic activity in those inoculated with ovine scrapie. 234 
Infected Tg388 mice at clinical stage obtained the lowest scores for LC3-B in all CNS 235 
areas analyzed (Fig. 1a), this downregulation being statistically significant in T (P = 236 
0.047), Ht (P = 0.028), Mes (P = 0.028), Pl (P = 0.015) and Mo (P = 0.023) compared to 237 
their controls (Fig. 1b). Moreover, the three first aforementioned areas and DCN also 238 
showed a significant decrease (P = 0.038 for T, 0.033 for Ht, 0.023 for Mes and 0.028 239 
for DCN, respectively) in clinical animals with respect to scrapie inoculated mice at 240 
preclinical stage of the disease. Preclinical scrapie mice displayed similar LC3-B scores 241 
than their age-matched controls (Supplementary Fig. 2a). In preclinical mice and the 242 
clinical control group, LC3-B immunohistochemical pattern was characterized by an 243 
intense and uniform intraneuronal immunolabelling affecting numerous cells, and by an 244 
abundant punctiform diffuse staining in the neuropil (Fig. 2). However, the clinical mice 245 
displayed a lower number of immunopositive cells and a slight neuropil 246 
immunolabelling. 247 
In contrast to LC3-B, p62 immunostaining was clearly stronger in brains from 248 
clinically-affected Tg338 mice (Fig. 1c). These animals seemed to accumulate the 249 
protein in all CNS areas analyzed, the increment being statistically significant in Ht (P = 250 
0.019), Ml (P = 0.019) and Pl (P = 0.038) when comparing to the preclinical mice, and 251 
in Ht (P = 0.045) when comparing to their control group (Fig. 1d). In addition, a 252 
tendency to upregulation was detected in Tc (P = 0.088), Pl (P = 0.095) and Wm (P = 253 
0.077) in clinical mice with respect to the control group. Similar to LC3-B, no 254 
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significant differences were detected between preclinical mice and their control group 255 
(Supplementary Fig. 2b), neither between control groups. Both neuronal and glial cells 256 
displayed a strong intracellular p62 immunolabelling in the clinical scrapie group, 257 
which also presented a remarkable granular staining of the neuropil (Fig. 3). Although 258 
presenting the same pattern, both the number of stained cells and the intensity of 259 
immunolabelling were lower in the preclinical and the control group.  260 
Dysregulation of LC3-B and p62 is associated to prion-related neuropathology 261 
To identify the relationship between scrapie-related lesions and autophagy, Spearman ρ 262 
correlation was calculated between immunohistochemical and histopathological scores. 263 
Table 1 shows correlation values and their statistical significance. Surprisingly, 264 
although LC3-B expression decreased in clinical mice, LC3-B immunostaining scores 265 
displayed a slight but statistically significant positive correlation with spongiform 266 
lesions in the total set of animals (ρ = 0.242, P < 0.001). However, this correlation 267 
seemed to be related with the preclinical stage of the disease where correlations were 268 
significant in both the total set (ρ = 0.462, P < 0.001) and only when the scrapie 269 
inoculated animals were analyzed (ρ = 0.426, P = 0.003). There was no correlation 270 
between the scrapie lesions and LC3-B in the clinical stage of the disease. In contrast, 271 
p62 expression was strong and positively correlated with spongiform lesions in all 272 
groups of individuals (ρ > 0.68, P < 0.001 for all cases). This correlation suggests a 273 
relationship between the accumulation of p62 and the course of the disease and degree 274 
of spongiform lesion. Intensity of prion deposition determined by PET blot negatively 275 
correlated with LC3-B immunostaining in the total set of scrapie inoculated animals 276 
(ρ = -0.473, P < 0.001) but not when the preclinical or clinical groups were separated. 277 
On the contrary, p62 immunostaining positively correlated with prion deposition in the 278 
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total set of scrapie animals (ρ = 0.300, P = 0.009) but not in the individual groups. 279 
These correlations confirm the decrease of LC3-B and increase of p62 in clinical 280 
animals but the observed distribution patterns do not seem to be related with the degree 281 
of PrPSc deposition. 282 
mRNA expression of Gas5, Atg5 and Fbxw7 is downregulated in the CNS of 283 
scrapie-infected Tg338 mice at clinical stage  284 
Murine models may provide valuable tools for analyzing the molecular mechanisms 285 
underlying the pathological processes in TSEs. In this work, transcripts from a selected 286 
group of genes encoding factors involved in autophagy were quantified in Mes and SC 287 
of the four Tg338 mouse groups. Mes is one of the most prion-affected brain areas in 288 
this murine model (Supplementary Fig. 1) and SC is adjacent to the medulla oblongata 289 
and therefore they share similar levels of scrapie neuropathology in sheep [36]. As 290 
shown in Fig. 4a, Gas5 displayed a significant downregulation (P = 0.03) in Mes of the 291 
clinical mice. In addition, a significant decrease of the expression of Atg5 (P = 0.04) and 292 
Fbxw7 (P = 0.03) was detected in SC of the same group (Fig. 4b). Significant changes 293 
were not detected at preclinical stage of the disease.  294 
DISCUSSION  295 
Prion diseases, progressive and fatal neurodegenerative disorders of humans and 296 
animals, are characterized by the accumulation of misfolded and aggregated PrPSc in the 297 
CNS, resulting in spongiform degeneration. Although autophagic vacuoles appear in 298 
several models of TSEs [26-30], little is known about how this process is involved 299 
during the course of the disease. Consequently, the relationship between autophagy and 300 
prion-related pathology is still open to debate. In a previous work, we investigated the 301 
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dynamics of autophagy in the CNS of sheep naturally affected with classical scrapie 302 
[31]. In this natural model, we described a possible impairment of autophagy in some of 303 
the most highly-affected brain regions, whereas mechanisms compatible with induction 304 
of autophagy were observed in less lesioned areas, suggesting a combination of anti-305 
prion and prion-promoting effects throughout the brain during the clinical stage of the 306 
disease. The impairment of autophagy in highly prion-affected brain areas was 307 
subsequently confirmed in sheep experimentally infected with atypical scrapie [32]. 308 
Murine models are widely used to perform in vivo assays and analyze the molecular 309 
mechanisms of the disease at different stages of the pathological process. In the present 310 
work, using a combination of immunohistochemical staining and real-time PCR 311 
quantification of markers involved in autophagy, we further investigated the role of 312 
autophagy in the Tg338 mouse model that overexpresses the most sensitive allele 313 
(VRQ) to classical scrapie infection of the ovine PRNP gene [33], in order to evaluate 314 
its potential as a model for the natural TSE. 315 
We first confirmed that clinical Tg338 mice display consistent similarities in 316 
neuropathological lesion profiles and PrPSc deposition patterns in PET blots to those 317 
observed in classical scrapie sheep [31]. The scrapie-inoculated Tg338 transgenic mice 318 
showed a minimal effect on Cbl and highest in T and brainstem. The presence of some 319 
spongiform lesions in the preclinical and control Tg338 mice could be related to the 320 
transgenic overexpression of PrPc, as also described by Westaway et al. [37]. 321 
As comparative analysis about LC3-B and p62 accumulation is necessary for the 322 
evaluation of autophagic activity [38, 39], we then investigated the dynamics of 323 
autophagy during prion pathogenesis in scrapie-infected Tg338 mice by estimating the 324 
expression levels of these proteins by IHC. Immunostaining assays are equally efficient 325 
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as Western blots to observe even slight changes of p62 aggregation and, in addition, 326 
they can also provide further information, such as the number, size and intracellular 327 
distribution of the aggregates [40].  328 
The protein p62 is a common constituent of neuronal and glial inclusions in various 329 
neurodegenerative diseases, such as AD and PD [41-43]. Furthermore, it is induced as a 330 
response to the expression of mutant huntingtin [44]. Our study did not reveal 331 
differential p62 regulation at the transcript level but the amount of this protein increased 332 
significantly in Ht and some cerebellar layers of scrapie-infected Tg338 mice at clinical 333 
stage. These animals also displayed p62 immunolabelling in glial cells. In agreement 334 
with our results, levels of p62 protein increase in prion-infected cell cultures and in 335 
brains of scrapie 263K-infected hamsters and scrapie 22L-infected mice [45]. In the 336 
latter study, LC3-II protein was also upregulated in 22L-inoculated mice, suggesting 337 
that activation of p62 could promote the clearance of PrPSc through the involvement of 338 
autophagic degradation. In contrast, scrapie-infected mice at clinical stage in our study 339 
displayed a significant downregulation of LC3-B at the protein level in the most prion-340 
affected areas (i.e. T, Ht, Mes and Mo) and in some cerebellar layers, such as Pl and 341 
DCN. The interpretation of the results based on the detection of autophagy markers is 342 
not straightforward. Whereas some studies relate the inhibition of autophagy with an 343 
increase of LC3-II levels [46], many others consider that the increment of LC3-II 344 
reflects an induction of autophagy [45, 47, 48]. This increment is accompanied by a 345 
downregulation of p62 in the terminal stage of 263K-infected hamsters and in human 346 
genetic prion diseases [48] and an upregulation of p62 in neuron cells treated with 347 
amino-terminally truncated prion protein (PrP90-231) [47]. However, the latter study 348 
suggested that PrP peptide stimulates autophagic flux but leads progressively to the 349 
accumulation of autophagolysosomes with impaired resolution ability, because it is 350 
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widely accepted that autophagic flux inhibition leads to p62 accumulation [49]. 351 
Consequently, the increment of p62 and the downregulation of LC3-B in our 352 
experimental model does not seem to reflect an enhancement of autophagic activity but 353 
an impairment of it, which would promote the progression of the disease during the 354 
terminal stages.  355 
Our molecular results regarding the expression of autophagy-related genes are also in 356 
agreement with the possible inhibition of the autophagy pathway. The rationale for 357 
selecting the genes for the expression studies was that they are positive regulators of 358 
autophagy through their action on formation of autophagic vesicles directly (Atg5) [50], 359 
indirectly through microRNA sponging (Gas5) [51], or through inhibition of mTOR 360 
complex (Fbxw7) [52]. Here, we have described a downregulation of Atg5 in SC of 361 
clinical-stage Tg338 mice, but not in the preclinical group. Neuron deletion of Atg5 in 362 
mice causes accumulation of ubiquitinated proteins, damaged organelles and autophagy-363 
specific substrates such as p62 [53]. In addition, downregulation of mRNA levels of 364 
beclin-1 and Atg5 in brains of scrapie-infected wild-type mice has been associated with 365 
an impairment of autophagy [17]. Our results also mimics the negative regulation of 366 
ATG5 in T observed in clinically scrapie-infected sheep [31].  367 
In the same animals and tissue, also Fbxw7 mRNA was downregulated. Knockdown of 368 
Fbxw7 inhibits autophagic flux and increases PrPSc accumulation in SMB-S15 cells 369 
infected with brains of scrapie-agent 263K [52]. Moreover, the expression of the long 370 
non-coding RNA Gas5 decreased in mesencephalon of scrapie-infected mice at clinical 371 
stage. Alterations in the expression of Gas5 have been reported in a range of animal 372 
pathological models [54] but it has not been investigated in prion diseases before. 373 
Depletion of Gas5 results in decreased autophagy in NSCLC cells [55] and, in epithelial 374 
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cells, knockdown of Gas5 suppresses the expression of LC3-II, ATG3 and ATG5-375 
ATG12 complex formation, whereas p62 levels are promoted [56]. Although further 376 
studies are needed to completely define the role of some of these regulatory factors in 377 
the specific conditions of prion infection, the above-mentioned findings on autophagy 378 
genes together with the decrease of LC3-B protein and the accumulation of p62 in the 379 
clinical mice group suggest that autophagic machinery is impaired during the late stage 380 
of prion infection. 381 
To conclude, the specific role of autophagy in prion diseases is still controversial. 382 
However, there is good evidence that autophagic process decreases in misfolded 383 
protein-mediated neurodegenerative diseases like Alzheimer’s [57] or Huntington’s [58] 384 
diseases. The present data suggest that autophagy is part of the pathological process and 385 
that modulation of autophagic capacity could play an essential role in the pathogenesis 386 
of prion diseases. The negative regulation of autophagy-related genes and the 387 
upregulation and downregulation of p62 and LC3-B proteins, respectively, observed in 388 
clinical scrapie-infected mice, but not in the preclinical group, likely reflect an 389 
impairment of the autophagic pathway that seems to take place at the last stage of the 390 
disease. Moreover, the absence of changes in autophagy regulation at preclinical stage 391 
suggests the impairment of autophagy at clinical stage is not the result of depletion or 392 
exhaustion of the autophagic machinery as suggested by our previous results in natural 393 
scrapie, where changes compatible with autophagy induction were observed in less 394 
affected CNS areas [31]. These discrepancies with the natural model may be related to 395 
the more aggressive disease development in the experimental transgenic model used 396 
and, therefore, the findings described here may not fully reflect the mechanisms 397 
underlying the natural disease. Although further studies involving late preclinical 398 
animals, different strains and experimental models are needed to clarify these 399 
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discrepancies, the alteration of autophagy during the clinical stage of the disease and the 400 
resemblance of prion neuropathology between both models demonstrate the suitability 401 
of Tg338 murine model to study the implication of autophagy in prion diseases. 402 
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FIGURE LEGENDS 638 
Figure 1: Semi-quantitative scoring of LC3-B and p62 in the CNS of Tg338 639 
scrapie-infected mice. Figure shows (a and c) global graphs and (b and d) comparative 640 
graphs of clinical group (black bars) with preclinical (grey bars) and control group (grey 641 
striped bars). Comparative graphs between preclinical and their control group, and 642 
between control groups, are not shown because no significant differences were detected. 643 
Score values (from 0: negative, to 5: staining present at its maximum intensity) 644 
evaluated in frontal cortex (Fc), septal area (Sa), thalamic cortex (Tc), hippocampus 645 
(Hc), thalamus (T), hypothalamus (Ht), mesencephalon (Mes), cerebellum [which 646 
includes molecular layer (Ml), Purkinje layer (Pl), granular layer (Gl), white matter 647 
(Wm) and deep cerebellar nuclei (DCN)] and medulla oblongata (Mo). The differences 648 
between the experimental groups were determined using the Mann Whitney U test (▪P < 649 
0.1 and *P < 0.05).  650 
Figure 2: Immunostaining patterns of LC3-B in different CNS areas of Tg338 651 
scrapie-infected mice. Figure shows representative images of LC3-B immunostaining 652 
in the clinical (middle), preclinical (right) and control group (left) (50 µm). Clinical 653 
scrapie-infected mice displayed a lower number of immunopositive cells and a slight 654 
neuropil immunolabelling in thalamus, hypothalamus and mesencephalon compared to 655 
the preclinical and control groups. In cerebellum, significant downregulation of LC3-B 656 
was observed in Purkinje layer in clinical mice when comparing with their control 657 
group, and in the deep cerebellar nuclei when comparing to the preclinical group. In 658 
medulla oblongata LC3-B was significantly decreased in clinical mice compared to their 659 
control group, but also a tendency to downregulation was observed with respect to the 660 
preclinical scrapie mice. Notice the abundant punctiform staining in the neuropil in deep 661 
cerebellar nuclei and medulla oblongata (arrowheads). 662 
25 
Figure 3: Immunostaining patterns of p62 in different CNS areas of Tg338 scrapie-663 
infected mice. Figure shows representative images of p62 immunostaining in the 664 
clinical (middle), preclinical (right) and control group (left) (50 µm). p62 665 
immunostaining was significantly stronger in hypothalamus in clinical mice compared 666 
to the preclinical and control groups, and in molecular layer and Purkinje layer of 667 
cerebellum compared to the preclinical group. Notice the glial cell immunolabelling 668 
(arrowheads and detail).   669 
Figure 4: Gene expression profiles of Atg5, Lc3, Fbxw7, p62 and Gas5 in Tg338 670 
scrapie-infected mice. Graphics show mRNA expression profiles in (a) mesencephalon 671 
and (b) cervical spinal cord, in preclinical (left, grey bars) and clinical (right, black 672 
bars) Tg338 scrapie-infected mice. Relative expression levels are expressed as mean ± 673 
standard deviation (SD). Results were normalized using the expression of Sdha 674 
housekeeping gene. The expression values were determined using the 2-ΔΔCt method and 675 
results were analyzed with the Student´s t-test (*P < 0.05). 676 




Table 1. Spearman correlation values between scores of autophagy markers (LC3-B 
and p62) and scrapie-related histopathological lesions (spongiform changes and PrPSc 
deposition) in the preclinical and clinical stage, in the total set of animals and only in 
scrapie inoculated mice.  
Correlations were estimated using the full set of data obtained in all tissues. 
N.S.: No statistically significant value.  
(Spearman correlation, **P < 0.01 and ***P < 0.001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preclinical stage Clinical stage 
Total set 
Scrapie 
clinical + 
preclinical Control + 
Scrapie Scrapie 
Control + 
Scrapie Scrapie 
LC3-B       
Spongiosis 0.462*** 0.426*** 0.09 N.S. 0.271 N.S. 0.242*** 0.180 N.S. 
PrPSc ---- -0.203 N.S. ---- -0.054 N.S. ---- -0.473*** 
p62       
Spongiosis 0.720*** 0.760*** 0.682*** 0.768*** 0.700*** 0.766*** 
PrPSc ---- -0.040 N.S. ---- 0.235 N.S. ---- 0.300** 
